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Introduction
Interleukin-36-receptor antagonist deficiency (DITRA) is
a recently described auto-inflammatory disease1, charac-
terized by repeated flares of generalized pustular psoria-
sis, high fever, asthenia and systemic inflammation. This
condition is caused by homozygous missense mutation
in the IL36RN gene, encoding the interleukin-36-receptor
antagonist (IL-36Ra), an anti-inflammatory cytokine. We
report herein the first exhaustive clinical description of
an infant with DITRA, who was successfully treated with
anakinra.
Case report
Y.M. is the first son of Tunisian consanguineous parents
who developed, at two weeks of life, an erythematous
and scaly eruption, with subsequent rapid evolution
toward generalized pustular psoriasis. Afterwards, cuta-
neous flares of diffuse erythematous rash and pustules
involving the whole body appeared, with a once weekly
periodicity. Intense irritability was present during flares
without fever. Moreover, since 1 month of age the infant
presented diarrhea, dysphagia and reduced feeding rate,
with failure to thrive. Laboratory tests during acute
flares showed marked leukocytosis, thrombocytosis and
anemia without C-reactive protein elevation. Skin biopsy
and clinical presentation were consistent with pustular
psoriasis, nevertheless, the patient did not respond to
high-potency topical corticosteroids and retinoid acid.
As the patient presented repeated skin flares early after
birth, as well as serious constitutional distress with failure
to thrive, an auto-inflammatory syndrome like DIRA
(interleukine-1 receptor antagonist deficiency)[2] or
DITRA was considered. The hypothesis was reinforced
by parental consanguinity, and absence of skin lesions
improvement under standard topical treatment. Genetic
analyses showed a homozygous mutation in the IL36RN
gene (L27P) which represents the same mutation recently
described in DITRA patients[1,3]. At 6 months we
started treatment with the recombinant IL-1 receptor
antagonist anakinra with efficacy both on constitutional
symptoms and skin involvement.
Discussion
To the best of our knowledge, we report the first
detailed clinical description of an infant with DITRA.
Even if neonatal onset has been already reported[1], no
detailed clinical description was provided, probably due
to late diagnosis. Our clinical report brings new clinical
characteristics and educational iconography.We even
report, for the first time, a favorable clinical response of
this disease to anakinra treatment.
Disclosure of interest
L. Rossi-Semerano: None Declared, M. Piram: None
Declared, C. Chiaverini: None Declared, D. De Ricaud:
None Declared, A. Smahi: None Declared, I. Koné-Paut
Grant / Research Support from: Educational and research
grant from Swedish Orphan Biovitrum, Consultant for:
Consultant fee from Novartis
Authors’ details
1Department of Paediatrics and Paediatric Rheumatology, Bicêtre Hospital,
National Reference Centre for Auto-inflammatory Diseases, Le Kremlin-
Bicêtre, France. 2Service de dermatologie et centre de référence des
épidermolyses bulleuses héréditaires Hôpital Archet 2 CHU de Nice, France.
3Service de pédiatrie, GCS CHU-Lenval, Nice, France. 4U781 INSERM, Hôpital
Necker Enfants Malades, Paris, France. 5Department of Paediatrics and
Paediatric Rheumatology, Bicêtre Hospital, National Reference Centre for
Auto-inflammatory Diseases, Le Kremlin Bicêtre, France.
Published: 8 November 2013
1Department of Paediatrics and Paediatric Rheumatology, Bicêtre Hospital,
National Reference Centre for Auto-inflammatory Diseases, Le Kremlin-
Bicêtre, France
Full list of author information is available at the end of the article
Rossi-Semerano et al. Pediatric Rheumatology 2013, 11(Suppl 1):A152
http://www.ped-rheum.com/content/11/S1/A152
© 2013 Rossi-Semerano et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
References
1. Marrakchi S, Guigue P, Renshaw BR, et al: Interleukin-36-receptor
antagonist deficiency and generalized pustular psoriasis. N Engl J Med
2011, 365(7):620-8.
2. Aksentijevich I, Masters SL, Ferguson PJ, et al: An Autoinflammatory
Disease with Deficiency of the Interleukin-1–Receptor Antagonist. N Engl
J Med 2009, 360(23):2426-2437, doi:10.1056/NEJMoa0807865.
3. Onoufriadis A, Simpson MA, Pink AE, et al: Mutations in IL36RN/IL1F5 are
associated with the severe episodic inflammatory skin disease known as
generalized pustular psoriasis. Am J Hum Genet 2011, 89(3):432-437.
doi:10.1186/1546-0096-11-S1-A152
Cite this article as: Rossi-Semerano et al.: PW02-012 - First clinical
description of an infant with DITRA. Pediatric Rheumatology 2013 11
(Suppl 1):A152.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rossi-Semerano et al. Pediatric Rheumatology 2013, 11(Suppl 1):A152
http://www.ped-rheum.com/content/11/S1/A152
Page 2 of 2
